IMNM
- Immunome, Inc.
()
Overview
Company Summary
Immunome, Inc. is a biotechnology company that specializes in discovering and developing innovative antibody-based therapeutics. The company focuses on harnessing the power of the human immune system to identify and target antigens associated with various diseases.
Immunome utilizes its proprietary antibody discovery platform called Human Memory B Cell (HMBC) technology. This platform enables the company to isolate and functionally interrogate rare immune cells, known as memory B cells, which are responsible for generating antibodies in response to infections or diseases.
By studying these memory B cells, Immunome aims to identify and isolate highly specific antibodies that have the potential to recognize and neutralize disease targets. The company's research efforts are centered around infectious diseases, including viral pathogens such as COVID-19, as well as other areas such as oncology.
Immunome's innovative approach involves rapidly screening and validating large numbers of potential antibody candidates using advanced technologies. Once promising antibodies are identified, the company pursues their development as therapeutic solutions. These antibodies can be used alone or in combination with other treatments to combat diseases and improve patient outcomes.
In addition to its antibody discovery platform, Immunome also collaborates with academic institutions and industry partners to further expand its technological capabilities and pipeline of therapeutic candidates. The company's ultimate goal is to create novel antibody-based therapies that address unmet medical needs and provide potentially life-saving treatments for patients suffering from various diseases.